Cost-effectiveness of rituximab (MabThera®) in diffuse large B-cell lymphoma in the Netherlands

European Journal of Haematology

Volumn 74, Issue 3, 2005, Pages 194-202

  Groot, Martijn T ^a   Lugtenburg, P J ^a   Hornberger, J ^a   Huijgens, P C ^a   Uyl De Groot, C A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CHOP; Cost effectiveness; Diffuse large B cell lymphoma; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; NETHERLANDS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUDGETS; COST-BENEFIT ANALYSIS; DECISION MAKING; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MONTE CARLO METHOD; NETHERLANDS; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 14044263505     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00368.x     Document Type: Article

References (25)

1. VISSER O, SIESLING S, VAN DIJCK JA.A.M. Incidence of Cancer in the Netherlands 1999/2000. Utrecht: Vereniging van Integrale Kankercentra, 2003.
2. KROL AD, LE CESSIE S, SNIJDER S, KLUIN-NELEMANS JC, KLUIN PM, NOORDIJK EM. Non-Hodgkin's lymphoma in the Netherlands: results from a population-based registry. Leuk Lymphoma 2003;44:451-458.
3. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
4. COIFFIER B, LEPAGE E, BRIERE J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
5. PFREUNDSCHUH MG, TRUMPER L, MA D, OSTERBERG A, PETTENGELL R, TRNENY M, SHEPHERD L, WALEWSKI J, ZINZANI P.-L, LOEFFLER M. Randomized Intergroup Trial of First Line Treatment for Patients ≤ 60 years with Diffuse Large B-cell non-Hodgkin's Lymphoma (DLBCL) with a CHOP-Like Regimen with or without the anti-CD20 Antibody Rituximab - Early Stopping after the First Interim Analysis. Abstract number 6500. New Orleans, Louisiana: ASCO, 2004.
6. NICE, National Institute of Clinical Excellence. Full guidance on rituximab for aggressive non-Hodgkin's Lymphoma. Technology Appraisals Series No. 65. London: NICE, 2003.
7. National Health Tariffs Authority. Policy for Expensive Medications in Hospitals. Utrecht: National Health Tariffs Authority, 2004.
8. Pharmo. Pharmo, Costs of Medications in Hospitals, Now and in the Future (in Dutch). Utrecht: Pharmo, 2002.
9. KNIGHT C, HIND D, BREWER N, ABBOTT V. Rituximab (MabThera) for Aggressive non-Hodgkin's Lymphoma: Systematic Review. Sheffield: The University of Sheffield, School of Health and Related Research on behalf of NICE for the NHS R & D HTA programme, 2003:81.
10. CHESON BD, HORNING SJ, COIFFIER B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
11. VAN AGTHOVEN M, FABER LM, UYL-DE GROOT CA, SONNEVELD P, VERDONCK LF, WILLEMZE R, KLUIN-NELEMANS JC, LOWENBERG B, HUIJGENS PC. Cost analysis of CHOP (-like) chemotherapy regimens for patients with newly diagnosed aggressive non-Hodgkin's lymphoma. Eur J Haematol 2002;69:213-220.
12. OOSTENBRINK JB, KOOPMANSCHAP MA, RUTTEN FF.H. Manual for Costing Research (in Dutch). Vol. 1. Amstelveen: Health care board, 2000.
13. KALBFLEISCH JD, PRENTICE RL. The Statistical Analysis of Failure Time Data. New York: Wiley, 1980:336.
14. DOORDUIJN JK, BUIJT I, VAN DER HOLT B, UYL-GROOT DE CA, SONNEVELD P. The Self-Reported Quality of Life (QoL) during Chemotherapy (CHOP) in Elderly Patients with Aggressive non-Hodgkin's Lymphoma (NHL). personal communication, 2003.
15. DOORDUIJN JK, BUIJT I, VAN DER HOLT B, VAN AGTHOVEN M, SONNEVELD P, UYL-DE GROOT CA. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin s lymphoma. Haematologica 2004;89:1109-1117.
16. GOLD MR, SIEGEL JE, RUSSELL LB, WEINSTEIN MC. Cost-Effectiveness in Health and Medicine. 1st edn. New York: Oxford University Press, 1996:425.
17. VAN LOENEN AC. Pharmacotherapeutical Compass 2003. Amstelveen: Health Care Board, 2003.
18. National Health Tariffs Authority. Healthcare Tariffs 2004. Utrecht: National Health Tariffs Authority, 2004.
19. PFREUNDSCHUH M, TRUMPER L, KLOESS M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634-641.
20. PFREUNDSCHUH M, TRUMPER L, KLOESS M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626-633.
21. Dutch Institute for Healthcare Improvement CBO. CBO, Treatment and Prevention of Coronary Heart Diseases by Plasma Cholesterol Lowering. Utrecht: Dutch Institute for Healthcare Improvement CBO, 1998:96.
22. POLEY MJ, STOLK EA, BROUWER WB, VAN BUSSCHBACH JJ. 'Necessity' determined on the basis of disease severity when prioritising health care interventions. Ned Tijdschr Geneeskd 2002;146:2312-2315.
23. DOORDUIJN JK, VAN DER HOLT B, VAN IMHOFF GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3041-3050.
24. VAN AGTHOVEN M, FABER L, UYL-DE GROOT CA. Diagnosis, Treatment and Follow-Up of the Intermediary and High Grade Non-Hodgkin Lymphoma (in Dutch). Rotterdam: iMTA, 2001.
25. DRUMMOND MF, O'BRIEN B, STODDART GL, TORRANCE GW. Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford University Press, 1997.